Noven gets warning letter from FDA related to Miami facility

Jan 10 (Reuters) - Noven Pharmaceuticals Inc NOVN.O said it received a warning letter from U.S. health regulators related to certain deficiencies in Current Good Manufacturing Practices at its Miami facility.

The letter does not restrict production or distribution of Daytrana, a skin patch for treatment of attention-deficit hyperactivity disorder, the company said in a statement. The U.S. Food and Drug Administration has sought additional information related to the deficiencies, the company said. (Reporting by Anant Vijay Kala in Bangalore; Editing by Deepak Kannan)